Markets:

Overview

News

Currencies

International

Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

3.670 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

3 Biotech Stocks to Buy Before Drug Trials End ↗

July 28, 2023

Drug trials are a chance for high risk, high reward investing. These stocks doing neurodegenerative trials could be set for big gains.

Via InvestorPlace

Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference

July 18, 2023

From Annovis Bio, Inc.

Via Business Wire

Annovis Bio Announces the Filing of a Groundbreaking Patent

June 27, 2023

From Annovis Bio, Inc.

Via Business Wire

Recap: Annovis Bio Q1 Earnings ↗

May 11, 2023

Via Benzinga

Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)

June 20, 2023

From Annovis Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 03, 2023

Via Benzinga

Tesla, NIO And Other Big Stocks Moving Lower On Monday ↗

April 03, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 03, 2023

Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 03, 2023

Via Benzinga

Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead ↗

March 31, 2023

The Dow Jones Industrial Average is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data.

Via Talk Markets

Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 31, 2023

Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.

Via Benzinga

Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday ↗

March 31, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 27, 2023

Via Benzinga

Dear PSNY Stock Fans, Mark Your Calendars for Oct. 12 ↗

October 06, 2022

Fans of Polestar Automotive (PSNY) stock will want to keep an eye on the company as a potential catalyst is coming on Oct. 12.

Via InvestorPlace

Why Is Annovis Bio (ANVS) Stock Up 12% Today? ↗

October 06, 2022

Annovis Bio (ANVS) stock is getting a boost on Thursday following news that the company will proceed with its Alzheimer's clinical trial.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 06, 2022

Gainers Statera BioPharma (NASDAQ:STAB) stock increased by 64.8% to $0.23 during Thursday's pre-market session. The company's market cap stands at $11.5 million.

Via Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday ↗

September 21, 2022

Gainers

Via Benzinga

Stocks Deepen Losses As Treasury Yields Soar ↗

September 20, 2022

The Dow Jones Industrial Average is deepening this morning's losses, down nearly 320 points at last check, as the Federal Open Market Committee's (FOMC) two-day policy meeting gets underway.

Via Talk Markets

S&P 500 Down 0.6%; Crude Oil Falls Sharply ↗

September 15, 2022

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 15, 2022

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday ↗

September 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in...

Via Benzinga

Why Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session ↗

September 09, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares jumped 70% to $2.1750 after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 09, 2022

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗

September 09, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...

Via Benzinga

Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off ↗

August 24, 2022

Annovis Bio, Inc. (NYSE: ANVS) has initiated patient dosing in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD). The Phase 3 trial is designed to evaluate the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022 ↗

September 08, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Annovis Bio, Inc. Common Stock (NY:ANVS)

All News about Annovis Bio, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today